Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Common Equity (2019 - 2025)

Vivos Therapeutics' Common Equity history spans 7 years, with the latest figure at -$1.5 million for Q4 2025.

  • Quarterly results put Common Equity at -$1.5 million for Q4 2025, down 119.49% from a year ago — trailing twelve months through Dec 2025 was -$1.5 million (down 119.49% YoY), and the annual figure for FY2025 was -$1.5 million, down 119.49%.
  • Common Equity for Q4 2025 was -$1.5 million at Vivos Therapeutics, down from $2.5 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $36.5 million in Q2 2021 to a low of -$1.5 million in Q4 2025.
  • The 5-year median for Common Equity is $6.7 million (2023), against an average of $10.1 million.
  • The sharpest move saw Common Equity surged 16563.04% in 2024, then plummeted 119.49% in 2025.
  • Year by year, Common Equity stood at $25.5 million in 2021, then plummeted by 81.2% to $4.8 million in 2022, then plummeted by 91.44% to $411000.0 in 2023, then surged by 1835.28% to $8.0 million in 2024, then crashed by 119.49% to -$1.5 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at -$1.5 million, $2.5 million, and $4.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.